16th Annual Perspectives in Thoracic Oncology

18. 11. 2011 - 19. 11. 2011, New York, USA

Témata

  • Surgery and staging
  • Radiation oncology
  • Adjuvant therapy
  • Special topics in thoracic oncology
  • Advanced NCSLC
  • Targeted therapies and immunomodulation
  • Biomarkers

Registrace

Program

Session I: Introductory lectures

8:00 am Welcome

8:10 am Lung cancer screening in 2011: Current reality and results from recent clinical trials

8:30 am Therapeutic economics and implications

8:50 am Pathology: What is the most effective and practical way of assessing molecular markers?

9:10 am Panel discussion and knowledge/confidence assessment of the audience via ARS survey

9:30 am Break

Session II: Surgery and staging

9:50 am Pre-activity knowledge/confidence assessment of the audience via ARS survey

9:55 am The intricacies of staging in NSCLC

10:15 am Debate: Surgery versus radiation therapy in patients with operable early stage NSCLC

10:45 am Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

11:05 am Lunch

Session III: Radiation oncology for the uninitiated and perpetually perplexed

12:40 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey

12:45 pm State of the art combined modality therapy

1:05 pm Integrating modern imaging and technology with therapy in LA-NSCLC

1:25 pm Novel approaches to radiation therapy in the palliative settings

1:45 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

Session IV: Prevention and early stage NSCLC

2:05 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey

2:10 pm Rethinking strategies for chemoprevention in lung cancer

2:30 pm Ongoing clinical trials in the adjuvant arena

2:50 pm Adjuvant therapy: State of the art in 2011

3:10 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

3:30 pm Break

Session V: Special topics in thoracic oncology

3:50 pm Esophageal cancer: Therapeutic updates

4:10 pm New insights in the management of mesothelioma

4:30 pm SCLC: An orphan disease. Who will adopt?

4:50 pm Updates on thymoma

5:10 pm Panel discussion and knowledge/confidence assessment of the audience via ARS survey

5:30 pm Closing notes and adjourn

Session VI: Advanced NSCLC

8:00 am Welcome to day two

8:05 am Pre-activity knowledge/confidence assessment of the audience via ARS survey

8:10 am Using histology to personalize therapy

8:30 am Role of EGFR TKIs as front line therapy in mutation positive patients with NCSLC

8:50 am Is ERCC1 and RRM1 ready for prime time?

9:10 am Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

9:30 am Break

9:50 am Pre-activity knowledge/confidence assessment of the audience via ARS survey

9:55 am Debate: What is the optimal extended therapy approach?

10:40 am Therapeutic options in the salvage setting

11:00 am What options exist for patients with compromised performance status

11:20 am Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

11:40 am Lunch

Session VII: Supportive therapy

12:40 pm Practical tips on the management of toxicities with EGFR and VEGFR inhibitors

1:00 pm Preventing myelosuppression in treatment of advanced disease

1:20 pm Management of bone metastases in NSCLC

1:40 pm Panel discussion and knowledge/confidence assessment of the audience via ARS survey

Session VIII: Biomarkers

2:00 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey

2:05 pm EML4/ALK and other new biomarkers and their therapeutic implications

2:25 pm The expanding role of proteomics

2:45 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

3:05 pm Break

Session IX: Targeted therapies

3:25 pm Pre-activity knowledge/confidence assessment of the audience via ARS survey

3:30 pm Angiogenesis inhibition: Bevacizumab and beyond

3:50 pm MET kinase inhibitors as therapeutic agents

4:10 pm New targeted agents on the horizon

4:30 pm Immunotherapy: Has its time arrived?

4:50 pm Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

5:10 pm Closing notes

5:15 pm Adjourn

Kontakt: meetings@imedex.com

Web: http://imedexinc.c...mp;scriptid=index1

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live